A Research Study for Patients With End-Stage Renal Disease (ESRD)

End Stage Renal Disease Clinical Trial

Official title:

An Open-Label, Randomised Study Using Cinacalcet to Improve Achievement of Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With ESRD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00110890
• Other study ID #: 20030187
• Status: Completed
• Phase: Phase 4
• First received: May 16, 2005
• Last updated: February 11, 2011
• Start date: May 2004
• Est. completion date: September 2007

Study information

• Verified date: February 2011
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 552
• Est. completion date: September 2007
• Est. primary completion date: April 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ESRD patients requiring maintenance dialysis (haemodialysis, haemodiafiltration, haemofiltration, or peritoneal dialysis) for at least 1 month

• The mean of 2 iPTH determinations within 21 days before randomization and drawn at least 2 days apart must be greater than or equal to 300 pg/mL (31.8 pmol/L) and less than 800 pg/mL (84.8 pmol/L). If biPTH is determined, the mean levels must be greater than or equal to 150 pg/mL (15.9 pmol/L) and less than 410 pg/mL (43.5 pmol/L)

• The mean of 2 serum calcium determinations (corrected for albumin) drawn on the same day as the PTH determinations must be greater than or equal to 8.4 mg/dL (2.1 mmol/L)

Exclusion Criteria:

• Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator

• Have had a parathyroidectomy in the 6 months before day 1

• Have received vitamin D therapy for less than 21 days before day 1 or required a change in prescribed vitamin D brand or dose within 21 days before day 1. If subjects are not prescribed vitamin D therapy, they must remain free of vitamin D therapy for the 21 days before day 1.

• Received, within 21 days before day 1 of the dose titration phase, therapy with medications that are predominantly metabolized by the enzyme CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine, and most tricyclic antidepressants). The tricyclic antidepressant amitriptyline is permitted. - Experienced a myocardial infarction within 3 months prior to day 1

• Are currently enrolled in, or have not yet completed at least 30 days before day 1, other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable)

• Have a gastrointestinal disorder that may be associated with impaired absorption or orally administered medications or an inability to swallow tablets

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Diseases
• Kidney Failure, Chronic

Intervention

Drug:
• cinacalcet
Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.

Other:
• Standard of care
Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

References & Publications (2)

Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F. The OPTIMA study: assessing a new cinacalcet (Sensipar/ — View Citation

Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P. Impact of vitamin D dose on biochemical parameters in patients wit — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Mean PTH = 300 pg/mL	Number of participants with mean parathyroid hormone (PTH) = 300 pg/mL during the efficacy assessment phase	Efficacy Assessment Phase (weeks 17 to 23)	No
Secondary	Number of Participants With Mean Ca x P < 55 mg^2/dL^2 and iPTH = 300 pg/mL	Number of participants with mean calcium x phosphorus (Ca x P) < 55 mg^2/dL^2 and intact parathyroid hormone (iPTH) = 300 pg/mL during the efficacy assessment phase	Efficacy Assesment Phase (weeks 17-23)	No
Secondary	Number of Participants With Mean Ca x P < 55 mg^2/dL^2	Number of participants with mean calcium x phosphorus (Ca x P) < 55 mg^2/dL^2 during the efficacy assessment phase	Efficacy Assessment Phase (weeks 17 to 23)	No
Secondary	Number of Participants With Mean Serum Ca < 9.5 mg/dL	Number of participants with mean serum calcium (Ca) < 9.5 mg/dL during the efficacy assessment phase	Efficacy Assessment Phase (weeks 17-23)	No
Secondary	Number of Participants With Mean Serum P < 5.5 mg/dL	Number of participants with mean serum phosphorus (P) < 5.5 mg/dL during the efficacy assessment phase	Efficacy Assessment Phase (weeks 17 to 23)	No

External Links

•   AmgenTrials clinical trials website
•   FDA-approved Drug Labeling